Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada

Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada

Abstract Background The risk of herpes zoster (HZ) increases with age and in immunocompromised (IC) patients. Recombinant zoster vaccine (RZV) is currently recommended in Canada for people aged ≥ 50 years. The objectives of the current study were to evaluate the cost-effectiveness and public health...

Full description

Saved in:
Bibliographic Details
Main Authors: Sydney George, Justin Carrico, Katherine A. Hicks, Dessi Loukov, Cheryl Ng, Desmond Curran
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Health Services Research
Subjects:
Recombinant zoster vaccine
Immunocompromised
Hematopoietic stem-cell transplant
Breast cancer
Renal transplant
Human immunodeficiency virus
Online Access:https://doi.org/10.1186/s12913-025-12550-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items